UNH trades 6.2% below Wall Street's consensus target of $425.81.
Last 12 months price action with 12-month analyst target path
The base valuation assumes UNH achieves its forward estimates and maintains a stable P/E multiple of 21.8x. This scenario reflects the blended consensus of 52 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, UnitedHealth Group Incorporated (UNH) has a Wall Street consensus price target of $425.81, based on estimates from 52 covering analysts. With the stock currently trading at $400.96, this represents a potential upside of +6.2%. The company has a market capitalization of $363.94B.
Analyst price targets range from a low of $361.00 to a high of $492.00, representing a 31% spread in expectations. The median target of $432.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 43 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 4 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, UNH trades at a trailing P/E of 30.3x and forward P/E of 21.8x. Analysts expect EPS to grow +38.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $675.26, with bear and bull scenarios of $425.41 and $889.72 respectively. Model confidence stands at 62/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
CVSCVS Health Corporation | $125.4B | $98.32 | $103.64 | +5.4% | Buy | 13.3x | 41 |
ELVElevance Health Inc. | $84.4B | $388.50 | $415.19 | +6.9% | Buy | 14.5x | 37 |
CICigna Corporation | $73.6B | $279.27 | $340.91 | +22.1% | Buy | 9.2x | 39 |
HUMHumana Inc. | $43.3B | $360.65 | $298.50 | -17.2% | Hold | 40.8x | 44 |
CNCCentene Corporation | $30.1B | $61.02 | $59.00 | -3.3% | Buy | 17.5x | 43 |
MOHMolina Healthcare, Inc. | $10.2B | $195.37 | $175.55 | -10.1% | Buy | 38.0x | 38 |
HCSGHealthcare Services Group, Inc. | $1.6B | $22.94 | $24.50 | +6.8% | Hold | 21.2x | 15 |
OSCROscar Health, Inc. | $7.4B | $28.40 | $24.20 | -14.8% | Hold | 31.5x | 11 |
CLOVClover Health Investments, Corp. | $2.6B | $5.00 | $4.47 | -10.6% | Hold | 129.2x | 9 |
ALHCAlignment Healthcare, Inc. | $4.5B | $21.86 | $24.33 | +11.3% | Buy | 118.7x | 16 |
Quick answers to the most common questions about buying UNH stock.
The consensus price target for UNH is $425.81, close to the current price of $400.96 (6.2% implied move). Based on 52 analyst estimates, the stock appears fairly valued near current levels.
UNH has a consensus rating of "Buy" based on 52 Wall Street analysts. The rating breakdown is predominantly bullish, with 43 Buy/Strong Buy ratings. The consensus 12-month price target of $425.81 implies 6.2% upside from current levels.
UNH trades at a forward P/E of 21.8029x, representing a moderate valuation. With analysts targeting $425.81 (6.2% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $492 for UNH, while the most conservative target is $361. The consensus of $425.81 represents the median expectation. Our quantitative valuation model projects a bull case target of $890 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
UNH is heavily covered by Wall Street, with 52 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 43 have Buy ratings, 5 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month UNH stock forecast based on 52 Wall Street analysts shows a consensus price target of $425.81, with estimates ranging from $361 (bear case) to $492 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $675, with bear/bull scenarios of $425/$890.
Our quantitative valuation model calculates UNH's fair value at $675 (base case), with a bear case of $425 and bull case of $890. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 62/100.
UNH trades at a forward P/E ratio of 21.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 30.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
UNH appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $425.81 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
UNH analyst price targets range from $361 to $492, a 31% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $425.81 consensus represents the middle ground. Our model's $425-$890 range provides an independent fundamental perspective.
Deep dive into UNH consensus models and risk factors.
Wall Street verdict, signals, and target summaries.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.